Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein.

BR2 Cytotoxicity Fusion protein IL24 IL24-BR2

Journal

Research in pharmaceutical sciences
ISSN: 1735-5362
Titre abrégé: Res Pharm Sci
Pays: Iran
ID NLM: 101516968

Informations de publication

Date de publication:
Aug 2019
Historique:
entrez: 14 9 2019
pubmed: 14 9 2019
medline: 14 9 2019
Statut: ppublish

Résumé

Interleukin (IL) 24 is a pro-inflammatory and tumor suppressor cytokine capable of inducing selective apoptosis in various cancer cells. BR2, on the other hand, is an anti-microbial peptide with selective penetrability to the cancer cells. In this study, we aimed to produce and purify a fusion protein containing IL24 as the toxic moiety fused to BR2, as targeting moiety, and then to evaluate its cytotoxic activities. For this purpose, the coding sequence of IL24-BR2 fusion protein and IL24 were cloned into the pET28a vector and used to transform

Identifiants

pubmed: 31516508
doi: 10.4103/1735-5362.263556
pii: RPS-14-320
pmc: PMC6714114
doi:

Types de publication

Journal Article

Langues

eng

Pagination

320-328

Références

J Clin Oncol. 2002 Feb 15;20(4):1069-74
pubmed: 11844832
Cancer Res. 2002 Aug 1;62(15):4273-81
pubmed: 12154029
Mol Cancer Ther. 2003 Jul;2(7):623-32
pubmed: 12883035
Cancer Biol Ther. 2003 Jul-Aug;2(4):347-53
pubmed: 14508103
Oncogene. 2004 Oct 7;23(46):7679-90
pubmed: 15334067
Mol Ther. 2005 Jan;11(1):149-59
pubmed: 15585416
Clin Cancer Res. 2005 Feb 1;11(3):1198-202
pubmed: 15709189
Protein Expr Purif. 2007 Jun;53(2):339-45
pubmed: 17292626
Mol Biotechnol. 2009 Feb;41(2):138-44
pubmed: 18953678
Mol Cancer Ther. 2009 May;8(5):1280-91
pubmed: 19417161
J Amino Acids. 2012;2012:967347
pubmed: 23316341
PLoS One. 2013 Jun 11;8(6):e66084
pubmed: 23776609
Protein Expr Purif. 2014 Feb;94:22-32
pubmed: 24211770
J Mol Signal. 2013 Dec 30;8(1):15
pubmed: 24377906
Adv Exp Med Biol. 2014;818:127-53
pubmed: 25001534
PLoS One. 2015 May 13;10(5):e0126390
pubmed: 25970292
Bioimpacts. 2015;5(2):103-11
pubmed: 26191505
Oncotarget. 2015 Nov 10;6(35):36928-42
pubmed: 26474456
J Microbiol Methods. 2016 Nov;130:100-105
pubmed: 27609715
Drug Deliv. 2017 Nov;24(1):986-998
pubmed: 28644728
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051

Auteurs

Marjan Pourhadi (M)

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Fahimeh Jamalzade (F)

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Ali Jahanian-Najafabadi (A)

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Fatemeh Shafiee (F)

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Classifications MeSH